EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies

Joe Y Chang iD, Xinyan Xu, Girish S Shroff, Nathan I Comeaux iD, Wei Li, Jordi Rodon Ahnert, Daniel D Karp, Ecaterina E Dumbrava, Vivek Verma, Aileen Chen, James Welsh, David S Hong iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009975 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Joe Y Chang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jychang@mdanderson.org dshong@mdand…. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Neoplasms, Radiosurgery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCRR NIH HHS, Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

BMS-986156 is an agonist of the glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) and promotes increased effector T-cell activation. Combined anti-GITR, anti-programmed death-1, anti-cytotoxic T-lymphocyte-associated protein 4 antibodies and radiotherapy improve tumor control in preclinical studies. Herein we describe the results of the safety and efficacy of BMS-986156+ipilimumab or nivolumab with/without stereotactic ablative radiotherapy (SABR) in patients with advanced solid cancers ( NCT04021043 ).

Methods

This open-label, multigroup, single-center phase I/II study enrolled patients with histologically-confirmed stage IV solid cancers resistant to standard treatments. Group 1 (G1, n=20) received four cycles of ipilimumab (3 mg/kg) plus BMS-986156 (30 mg as dose level 1 (L1) or 100 mg as dose level 2 (L2)), every 3 weeks (Q3W). Group 2 (G2, n=10) received four cycles of ipilimumab (3 mg/kg) plus BMS-986156 (dose as determined in G1, Q3W) with SABR (50 Gy/4 fx or 60–70 Gy/10 fx to liver/lung lesions. Group 3 (G3, n=20) received four cycles of nivolumab (480 mg) plus BMS-986156 (30 mg), every 4 weeks with SABR. Maintenance nivolumab could be given up to 2 years. Tumor responses were assessed every 1–3 months until progression, using immune-related response criteria.

Results

50 patients were enrolled between 10/2019 and 12/2021. Patients received a median of 3 (IQR 2–4.25) initial treatment cycles. 100 mg BMS-986156 with ipilimumab was tolerated well. Five discontinued BMS-986156 with ipilimumab due to treatment-related adverse events (TRAEs), with three in G1/L1, one in G1/L2 and one in G2, respectively. 22 patients (44%) experienced Grade 1–3 TRAEs (6, 4, 5, 7 patients for G1/L1, G1/L2, G2, G3). Six (12%) had Grade 3 TRAEs (2, 2, 1, 1 for G1/L1, G1/L2, G2, G3), with elevated alanine aminotransferase (n=3, in G1/L2, G2 and G3) and aspartate aminotransferase (n=2, in G2 and G3) being the most common. There was no Grade 4–5 TRAEs. Overall, 19/39 (48.7%) patients eligible for efficacy analysis had stable disease and 3 (7.7%) achieved a partial response. Out-of-field (abscopal) disease control rate (ACR) and out-of-field (abscopal) response rate (ARR) were 38.5% and 7.7%, respectively, with the highest ACR (50%, 9/18) and ARR (11.1%, 2/18) in G3.

Conclusions

BMS-986156 was well-tolerated with ipilimumab, nivolumab, with or without SABR. Outcomes were encouraging in this population, as more than half of patients had stable disease/partial response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabIpilimumabNeoplasmsRadiosurgeryHumansMaleFemaleAgedMiddle AgedAdultAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and over

Stichwörter der Autor:innen

abscopalimmunotherapyradiotherapy/radioimmunotherapy

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jychang@mdanderson.org dshong@mdanderson.org.
  • Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jychang@mdanderson.org dshong@mdanderson.org.

ORCID-Profile: Joe Y Chang, Nathan I Comeaux, David S Hong

Förderung

  • NCI NIH HHS
  • NCRR NIH HHS
  • Bristol Myers Squibb
  • The National Cancer Institute at the National Institutes of Health

Zitieren

APA

Chang, J. Y., Xu, X., Shroff, G. S., Comeaux, N. I., Li, W., Rodon Ahnert, J., Karp, D. D., Dumbrava, E. E., Verma, V., Chen, A., Welsh, J., & Hong, D. S. (2024). Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009975

Vancouver

Chang JY, Xu X, Shroff GS, Comeaux NI, Li W, Rodon Ahnert J, et al. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009975

BibTeX
@article{Chang2024,
  author = {Chang, Joe Y and Xu, Xinyan and Shroff, Girish S and Comeaux, Nathan I and Li, Wei and Rodon Ahnert, Jordi and Karp, Daniel D and Dumbrava, Ecaterina E and Verma, Vivek and Chen, Aileen and Welsh, James and Hong, David S},
  title = {Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009975}
}
Kostenlos starten →